Connect with us

Health

Twice-Yearly HIV Prevention Jab Clears Major Hurdle in Europe

Published

on

European regulators have taken a major step toward approving a groundbreaking HIV prevention treatment, with a twice-yearly injection from U.S. drugmaker Gilead Sciences receiving a positive opinion from the European Medicines Agency (EMA).

The injectable drug, known as lenacapavir, has been hailed as a “game-changer” in the global fight against HIV. Designed as a long-acting form of pre-exposure prophylaxis (PrEP), the treatment has shown 100% effectiveness in preventing HIV in clinical trials. It works by preventing the virus from replicating and spreading in the body, offering protection for both adults and adolescents.

The EMA’s advisory committee issued its endorsement last Friday, paving the way for formal approval by the European Commission later this year. Once authorized, lenacapavir will be marketed in the EU under the name Yeytuo.

“This milestone reflects our commitment to reimagine HIV prevention in Europe and around the world,” said Dr. Dietmar Berger, Chief Medical Officer at Gilead Sciences. “Lenacapavir for PrEP has the potential to become a critical tool for public health, helping to expand prevention options for people who face the highest barriers to care.”

Unlike existing daily oral PrEP medications, lenacapavir requires only two injections per year, making it a more convenient option and potentially improving adherence among at-risk populations.

Despite significant advancements in treatment and awareness, HIV continues to pose a public health challenge. In 2023, the number of new HIV diagnoses in the EU, along with Iceland, Liechtenstein, and Norway, rose to over 24,700—an 11.8% increase from the previous year.

Lenacapavir was also approved by the U.S. Food and Drug Administration (FDA) last month. While its rollout is expected to begin in Europe soon after final approval, global accessibility remains a concern.

See also  Overdiagnosis of Prostate Cancer May Explain Wide Variations in Incidence Across Europe, Study Finds

Gilead has agreed to license generic versions of the drug for use in 120 low- and middle-income countries with high HIV prevalence. However, the extent of global distribution is uncertain following significant funding cuts to international health programs by the United States earlier this year.

The European Commission, which will make the final decision on market authorization, has not yet issued a formal response. The EMA also declined to comment further at this stage.

If approved, lenacapavir would mark a major shift in HIV prevention strategies across Europe, potentially reaching those who struggle with daily medication regimens and expanding protection at a time when new infections are once again on the rise.

Health

AI Model Surpasses Doctors in Key Medical Decision Tests, Study Finds

Published

on

A new study by researchers at Harvard Medical School and Beth Israel Deaconess Medical Center has found that advanced artificial intelligence systems can outperform human doctors in several medical reasoning tasks, including diagnosis and emergency care decisions.

The research compared physicians with large language models across a range of clinical scenarios. According to the findings, AI systems showed stronger performance in tasks such as identifying likely diagnoses, recommending treatment steps, and making decisions in emergency department settings where information is often limited.

Arjun Manrai, a co-senior author of the study, said the results demonstrate the rapid progress of AI in healthcare. He noted that the model surpassed both earlier systems and physician benchmarks in most tests. At the same time, he cautioned that better performance in controlled settings does not guarantee improved outcomes in real-world care.

The study evaluated OpenAI’s reasoning model, released in 2024, using a mix of published clinical cases and real-world emergency department data. Researchers presented the system with patient scenarios at different stages of care, from initial triage to later admission decisions. At each step, the AI was given only the information available at that point and asked to suggest diagnoses and next actions.

The results showed that the AI consistently outperformed doctors, especially in areas requiring structured reasoning and documentation. The largest gap appeared during the triage stage, when limited information makes decision-making more difficult. As additional data became available, both AI and physicians improved in accuracy, though the AI maintained an edge in many cases.

Peter Brodeur, a co-author of the study, said traditional testing methods such as multiple-choice questions are no longer sufficient to measure progress, as many AI models now achieve near-perfect scores. He added that newer evaluation approaches are needed to track further advances.

See also  Drug-Resistant ‘Nightmare Bacteria’ Infections Surge Across US, CDC Warns

Despite the promising results, researchers stressed that the use of AI in healthcare must be approached carefully. They warned that while a model may correctly identify a diagnosis, it could also recommend unnecessary tests or interventions that might carry risks for patients.

The study’s authors called for further trials in real clinical environments to better understand how AI tools perform in practice. They also highlighted the need for investment in infrastructure and clear frameworks to support the safe use of such technologies.

The findings come with some limitations, as the analysis focused on a specific version of the AI model, which has since been updated. Researchers said additional studies are needed to compare different systems and explore how doctors and AI can work together effectively in patient care.

Continue Reading

Health

New Study Reveals How Coffee May Help Protect the Body From Ageing

Published

on

A new study has uncovered a key biological mechanism that may explain why coffee has long been linked to healthier ageing and a lower risk of chronic disease.

Researchers at Texas A&M College of Veterinary Medicine & Biomedical Sciences found that compounds in coffee interact with a protein in the body known as NR4A1, a receptor involved in regulating stress responses, inflammation and cellular repair. The findings shed new light on how coffee may help protect the body from age-related decline.

For years, studies have associated regular coffee consumption with a longer life and reduced risk of conditions such as heart disease, cancer and cognitive decline. Until now, however, the biological processes behind those benefits have remained largely unclear.

The research team identified NR4A1 as a critical target for several naturally occurring compounds in coffee, particularly polyphenols and other polyhydroxylated substances. These compounds bind to the receptor and appear to influence how it functions.

NR4A1 acts as what scientists call a nutrient sensor, responding to dietary compounds and helping the body adapt to stress and damage. It plays an important role in controlling inflammation, maintaining energy balance and promoting tissue repair — all essential processes in healthy ageing.

Stephen Safe, one of the study’s lead researchers, said the findings provide a clearer understanding of coffee’s protective effects. He explained that NR4A1 helps limit damage when tissues are under stress, and that its absence can worsen the effects of injury or disease.

Laboratory tests showed that coffee compounds reduced cellular damage and slowed the growth of cancer cells. When researchers removed NR4A1 from the cells, those benefits disappeared, strongly suggesting that the receptor is central to coffee’s protective action.

See also  EU Households Shoulder 15% of Health Costs, But Burden Varies Sharply Across Europe

The study also highlights that coffee’s health effects are likely driven by more than caffeine alone. Decaffeinated coffee has also been linked to improvements in learning and memory, indicating that other components, including polyphenols, may play a significant role.

Recent research has suggested that moderate consumption of caffeinated coffee may also reduce anxiety, improve attention and vigilance, and lower levels of inflammation.

Scientists caution that while the findings are promising, more research is needed to determine how significant the NR4A1 pathway is in humans and how it interacts with other biological systems.

Still, the discovery offers an important step toward understanding why coffee remains one of the most widely studied beverages in nutrition science. It also reinforces the idea that compounds found in everyday foods and drinks can play a meaningful role in supporting long-term health and resilience as people age.

Continue Reading

Health

Study Finds Rise in 11 Cancers Among Younger Adults in England

Published

on

A major study has found that rates of 11 types of cancer are increasing among younger adults in England, raising fresh concerns among researchers about factors driving the trend.

The study, conducted by the Institute of Cancer Research and Imperial College London, examined cancer diagnoses between 2001 and 2019 in adults aged 20 to 49. It identified rising incidence in a range of cancers, including breast, colorectal, pancreatic and kidney cancers.

The full list includes breast, colorectal, pancreatic, kidney, liver, gallbladder, thyroid, ovarian and endometrial cancers, as well as oral cancer and multiple myeloma, a form of blood cancer.

Researchers noted that for most of these cancers, rates have also increased among older adults, where cancer remains far more common. This suggests that some shared risk factors may be affecting multiple age groups.

Two cancers, however, stood out. Rates of colorectal and ovarian cancer rose only among younger adults, pointing to possible age-specific causes that are not yet fully understood.

Scientists examined a range of established cancer risk factors, including smoking, alcohol consumption, diet, physical activity and body weight. While these factors are known to contribute significantly to cancer risk, they do not appear to fully explain the recent rise in cases among younger people.

In fact, many of these traditional risk factors have either remained stable or improved over recent decades. Smoking rates have declined, alcohol consumption has generally fallen or levelled off, physical inactivity has decreased, and intake of red and processed meat has dropped.

Obesity was the notable exception. Rates of obesity have risen steadily across all adult age groups and remain a significant contributor to cancer risk. Even so, researchers found that obesity alone could not account for the broader increase in cancer diagnoses among younger adults.

See also  Study Finds Diminishing Returns in Health Spending After a Certain Threshold

This was particularly true for cancers commonly associated with excess body weight, such as bowel, kidney, pancreatic, liver, gallbladder and endometrial cancers. While rising obesity may be playing a role, it does not fully explain the trend.

The findings suggest that other factors may be contributing. Researchers say further investigation is urgently needed into possible causes, including environmental exposures, changes in diet or lifestyle during childhood, and other early-life influences.

They also pointed to the possibility that improved diagnostic tools, increased screening and greater public awareness may be leading to more cases being detected.

Public health experts say the study highlights the need for continued prevention efforts, particularly in tackling smoking and obesity, which remain more common in disadvantaged communities. As researchers work to better understand the causes, the rise in cancer among younger adults is likely to remain an important area of focus for health authorities.

Continue Reading

Trending